Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2Phase NA 1Phase 4 1Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 33Neoplasms 17Prostatic Neoplasms 14Lung Neoplasms 12Carcinoma, Hepatocellular 11Carcinoma, Non-Small-Cell Lung 10Multiple Myeloma 9Colorectal Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Papillomavirus Infections 6Pain, Postoperative 6Neoplasm Metastasis 6Leukemia, Myeloid, Acute 6Stomach Neoplasms 5Recurrence 5Liver Neoplasms 5Lymphoma, Non-Hodgkin 4Kidney Neoplasms 4Heart Failure 4Glioma 4Febrile Neutropenia 4Carcinoma, Renal Cell 4Brain Neoplasms 4Warts 3Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Skin Neoplasms 3Rectal Neoplasms 3Pituitary Neoplasms 3Pancreatic Neoplasms 3

Interventions

pembrolizumab 1enfortumab vedotin 1Specimen Handling 1Nephroureterectomy 1Magnetic Resonance Spectroscopy 1Hyperthermia, Induced 1Cystectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Recruiting × Ureteral Neoplasms × Clear all
NCT06764095 2026-02-12

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Mayo Clinic

Phase 4 Recruiting
75 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡